Managing Anemia in Pediatric Office
Introduction
Children's hematologic and oncologic problems often present initially to the pediatrician. This article provides direction for the diagnosis and office treatment of anemia and guidelines for follow-up and, where appropriate, referral to a subspecialist. Part 1 considers iron deficiency, beta-and alpha-thalassemia trait, and hereditary spherocytosis (Table 1) . Part 2 considers sickle cell syndromes, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and transient erythroblastopenia. These topics were proposed by practicing pediatricians in our communities as those of particular concern in their office practices.
Anemia
The traditional measurements of hemoglobin concentration and hematocrit may not be sufficient to determine the presence of anemia of childhood. The "normal values" cited in clinical pathology laboratory reports are unlikely to apply to children. Tables of normal  values for children of different ages have been published (Table 2 ). In general, the hemoglobin is high at birth and falls during the initial 6 to 8 weeks of life to a physiologic nadir before it gradually increases to childhood levels. Patients who suffer from cyanotic congenital heart disease or chronic obstructive pulmonary disease may have values that are considerably higher than children who do not have these problems. These children, therefore, may be anemic when their hemoglobin and hematocrit values are within the normal range for unaffected children. Once the physician has decided that the child's values are two standard deviations below the mean for his or her age group, the cause should be determined.
Iron Deficiency Due To Inadequate Dietary Iron or Chronic Bleeding History and Physical Examination
The child who has iron deficiency most often presents without symptoms; the condition is detected on routine screening or because of pallor or a low hemoglobin/hematocrit on a blood count performed for another reason. Dietary iron deficiency is most common between the ages of 1 and 3 years as a result of cow milk being a major staple of a child's diet. Cow milk is a very poor source of iron (0.7 mg/L). It is important to obtain a dietary milk history that catalogs precisely the number of bottles or glasses ingested per day, the quantity contained in those vessels, and whether the child drinks additional milk at the time he or she is put to bed or wakes during the night. A milk intake greater than 16 oz/24 h in an 18-to 24-monthold child should raise the question of whether dietary iron intake is adequate. The high satiation value of milk and the milk-induced delay in gastric emptying time interferes with the ingestion of adequate amounts of iron-containing foods, no matter what the parents may report in a dietary history. Little is found on physical examination beyond pallor; organ enlargement usually is not observed.
Pathogenesis, Signs, and Symptoms
Iron is required not only for the production of hemoglobin, but also for enzymes such as cytochromes that are present in all tissues. Thus, iron deficiency is a systemic disease that may be manifested by irritability and developmental delay. Severe dietary iron deficiency may result in trace amounts of blood in the stool because of the lack of cytochrome iron and gastrointestinal mucosal damage or because of milk allergy and enteropathy, but the test for occult blood should be no more than trace positive. The black stools resulting from concurrent iron treatment will not give false-positive results. In children younger than 9 months and older than 3 years of age, dietary iron deficiency is uncommon, and evaluation of the stool for blood loss becomes more important. Rarely, iron may be lost via urinary (intravascular hemolysis) or pulmonary bleeding (pulmonary hemosiderosis).
Laboratory Testing
Use of hemoglobin and hematocrit screening for iron deficiency remains controversial. Screening children between 6 months and 1 year and at 2 and 3 years of age can decrease the risk of the subtle adverse effects of iron deficiency on development. Approximately one third of patients who have iron deficiency anemia have a normal mean cell volume (MCV). Mild anemia of iron deficiency is normocytic and normochromic because the red cell size and hemoglobin fall through the normal range due to lack of iron. It then becomes hypochromic and microcytic, as assessed clinically by a mean corpuscular hemoglobin (MCH) below 25 pg/cell and an MCV below 78 fL/cell on the complete blood count or as reported on the blood film. The role of the MCV and reticulocyte percentage in categorizing the anemias is shown in Table  3 . If there is any doubt about the dietary history and the interpretation of the microcytosis and hypochromia, a serum iron and total iron binding capacity (TIBC) can be ordered and a percent saturation calculated. Normal serum iron levels are 22 to 184 mcg/dL (3.4 to 32.9 mcmol/L), TIBC is 100 to 400 mcg/dL (1 to 4 g/L) in infants and 200 to 400 mcg/dL (2 to 4 g/L) in older children, and percent saturation is more than 20%. In iron deficiency, the serum iron concentration is low and the TIBC is high (Table 4 ). An evaluation of the serum ferritin usually reflects the body iron stores in the absence of inflammatory disease, and it is low in iron deficiency.
Treatment
In a pale, irritable child who has a hypochromic microcytic anemia and a history of greater than 32 oz of whole milk intake per day, the diagnosis almost certainly is related to dietary lack of iron. Many pediatricians would treat such a child with supplemental iron without additional laboratory testing. Because some children may have gastrointestinal bleeding as the etiology of their iron loss, testing with stool occult blood cards on four to five separate occasions is indicated and inexpensive; negative results minimize the risk of this consideration. The treatment of iron deficiency depends on its etiology. For children who have dietary iron deficiency, the milk in the diet should be reduced promptly to fewer than 16 oz/d. Those children who have gastrointestinal bleeding should undergo imaging and endoscopy and receive appropriate treatment. Iron is administered as iron sulfate (25 mg/mL), and the usual dose for children is 6 mg/kg per day of elemental iron in three divided doses. Older children and adults can be given 325-mg ferrous sulfate tablets that contain 65 mg elemental iron, but they may tolerate only two to three tablets per day (2 to 3 mg/kg per day) because of iron-induced intestinal discomfort. Patients should be treated until the hemoglobin and hematocrit reach the normal range and given at least 1 month of additional treatment to replete the iron stores. Table 6 Also see Table 6 G6PD Deficiency Parvovirus
Indication for Referral
If the response to iron therapy is not adequate within 4 to 8 weeks or if the anemia recurs, there may be persistent bleeding, iron malabsorption, noncompliance, or other causes of a hypochromic and microcytic anemia. The pediatrician may consider evaluating the child for thalassemia trait or lead poisoning. The serum iron and the TIBC are low in chronic inflammatory disease, but the ferritin is elevated, an important distinction (Table 4 ). In this instance, the child should be evaluated for rheumatologic disorders or chronic infection. The ironrelated microcytic anemias, including iron deficiency, chronic inflammatory disease, and sideroblastic anemia, are compared in Table 4 . If the diagnosis is not clear, referral to a pediatric hematologist for consideration of less likely conditions, such as sideroblastic anemia, alpha-thalassemia, or combinations of these problems, is appropriate (Table 5) . Sideroblastic anemia is a preleukemic condition seen only rarely in children.
Beta-Thalassemia Trait History and Physical Examination
A family history of anemia or the presence of microcytosis and mild anemia in a patient from the Mediterranean region should alert the pediatrician to the possibility of beta-thalassemia trait. Similar findings in patients from southeast Asia suggest alphathalassemia trait, beta-thalassemia trait, or a hemoglobin E syndrome. The blood hemoglobin concentration usually is low-normal, and few or no symptoms may be attributed to it, but chronic fatigue and pallor may be present. The family's name may not suggest the relevant ethnicity, if, for example, the mother has taken the father's last name. It is particularly important to explore both the maternal and paternal sides of the family for a history of anemia because the potential for beta-thalassemia major or E-beta-thalassemia in future children is one of the primary reasons for establishing a diagnosis of beta-thalassemia trait or hemoglobin E in a patient. Aside from mild pallor, little is found on physical examination, and there is no enlargement of the liver or spleen in beta-thalassemia trait. Organomegaly suggests a more severe form of thalassemia.
Pathogenesis, Signs, and Symptoms
Beta-thalassemia trait results from a defect in a single beta-globin gene that results in diminished production of normal beta-globin chains and, hence, di- hematology anemia minished hemoglobin A and a resultant hypochromic and microcytic anemia. It is inherited as an autosomal recessive trait, and the risk for major thalassemia in a subsequent pregnancy is one in four if both parents are carriers. The diagnosis should be considered in a slightly pale, mildly anemic child of Mediterranean, Asian, or African ethnicity. If the child is between ages 1 and 3 years, dietary iron deficiency also should be considered (Table 5) , although failure to respond to therapy for presumptive iron deficiency anemia often leads to a diagnosis of thalassemia trait. Hemoglobin E is a beta-chain variant (alpha 2 beta 2 26Glu3 Lys ) that is produced in diminished amounts and, hence, is akin to thalassemia. The hemoglobin E syndromes are summarized in Table 6 . Patients who have hemoglobin E trait do not have anemia, but they do have microcytic red blood cells. Homozygous hemoglobin E disease is characterized by mild anemia and severe microcytosis without organomegaly, and E-betathalassemia is similar to beta-thalassemia major, with severe anemia, organomegaly from extramedullary hematopoiesis and hemolysis, and a requirement for red blood cell transfusion.
Use of Iron Studies in the Differential Diagnosis of Hypochromic Microcytic Anemias

Condition
Laboratory Testing
Beta-thalassemia trait is characterized by a mild anemia, with a hemoglobin of 9.5 to 11 g/dL (95 to 110 g/L) in prepubertal children and usually an MCV of less than 80 fL/cell (Table 6) . Older children will have values at or just below the normal values for their age and gender. Examination of the blood film often shows marked variation in size and shape of the red cells, with hypochromia and basophilic stippling. This basophilic staining represents precipitated RNA, which is seen with the standard Wright stain. Basophilic stippling is observed commonly among patients who have lead toxicity and betathalassemia trait but not among those who have iron deficiency, making it an important distinguishing feature. The reticulocyte percentage is not significantly elevated. Patients who have beta-thalassemia trait, in contrast to those who have iron deficiency, typically have an increased number of red cells that are smaller than normal, leading to a ratio of the MCV/red cell count per milliliter of less than 13. The ratio in iron deficiency usually is more than 13 (Mentzer index). Quantitative hemoglobin electrophoresis shows an elevation in the percentage of A 2 (alpha 2 , delta 2 ) hemoglobin of greater than 3.5% or an elevation in F (alpha 2 ,gamma 2 ) hemoglobin. Electrophoresis should not be performed if there is concurrent iron deficiency because this tends to reduce the level of A 2 hemoglobin and may obscure the diagnosis of thalassemia trait.
The presence of hemoglobin E is detected by hemoglobin electrophoresis. The features of the blood film and red cell indices are shown in Table 6 .
Treatment
No specific treatment is required for patients who have beta-thalassemia trait, hemoglobin E trait, or homozygous hemoglobin E. The importance of establishing these diagnoses is to avoid treatment for a deficiency of iron that is not present. It is critical to evaluate both mother and father to ensure that both do not carry a thalassemic gene. If both are affected with betathalassemia trait or with beta-thalassemia trait and hemoglobin E, there is a 25% risk of having a child who has a major thalassemia syndrome, a condition that requires chronic transfusion therapy and iron chelation and usually shortens the lifespan.
Indication for Referral
If there is a question about the diagnosis, the genetics, appropriate counseling, or subsequent evaluation, children suspected of having beta-thalassemia or hemoglobin E trait should be referred to a pediatric hematologist. These would include patients whose anemia is more severe than would be expected; they may have a confounding second reason for anemia or they may have beta-thalassemia intermedia, beta-thalassemia major, or E-beta-thalassemia, which present more complex diagnostic and therapeutic problems (Table 6 ). Betathalassemia major usually is recognized during the sec- ond half of the first year of life when gamma-chain and fetal hemoglobin (alpha 2, gamma 2 ) production fall. The child becomes progressively more anemic because there is little or no production of beta-chain or hemoglobin A (alpha 2, beta 2 ). The severe hypochromic microcytic anemia requiring transfusion and the resultant enlargement of the liver and spleen because of extramedullary hematopoiesis suggest the diagnosis of thalassemia major. Other causes of hypochromic microcytic anemias are shown in Table 5 .
Alpha-Thalassemias History and Physical Examination
Patients who have alpha-thalassemia trait (two-gene deletion alphathalassemia) usually are asymptomatic. Alpha-thalassemia trait should be considered when beta-thalassemia trait is suspected, but the A 2 and F hemoglobin levels are normal. It is seen most often in Asian populations but also may occur in persons of Mediterranean and African descent. Patients who have alpha-thalassemia trait have normal physical examination findings because anemia usually is not present. Only with more severe alpha-thalassemia syndromes, such as hemoglobin H disease, is there moderate anemia, usually characterized by a hemoglobin of 7 to 10 g/dL (70 to 100 g/L) and splenomegaly.
Pathogenesis, Signs, and Symptoms
Alpha-thalassemia trait should be suspected in patients of the appropriate ethnic background who have red cells with a decreased MCV, do not have iron deficiency, and present a normal hemoglobin A 2 by quantitative electrophoresis. Alphathalassemia trait results from the deletion of two alpha-globin genes, which impairs the production of glo- bin, but does not increase A 2 hemoglobin. Alphathalassemia differs between the Asian and African populations in that the two defective genes do not occur on the same chromosome in African-Americans (Fig. 1) . Thus, only the normal, silent carriers, and the alphathalassemia trait phenotypes are seen. The pathogenesis of the alpha-thalassemia syndromes involves a four-gene system, as shown in Fig. 1 . Unaffected people have four normal genes, two on each chromosome 16. The severity of the clinical syndrome depends on the number of genes that are defective. If one gene is inactive, there is no clinical phenotype, and the patient is designated a silent carrier of alpha-thalassemia. A two-gene deletion results in alpha-thalassemia trait that may occur either from one defective gene on each chromosome, as in African or Asian populations, or from two defective genes on a single chromosome, as in Asian populations. These patients have red blood cell microcytosis with little or no anemia. Three-and four-gene deletions occur almost exclusively in the Asian population. Three defective genes result in hemoglobin H disease. Hemoglobin H is composed of a tetrad of betachains because of the paucity of available alpha-chains, and it is characterized by a chronic hemolytic anemia with splenomegaly. Four defective genes preclude assembly of hemoglobin F or hemoglobin A, which results in a tetrad of four gamma genes in the newborn, termed Bart's hemoglobin. Bart's hemoglobinopathy produces a catastrophic anemia, hydrops fetalis, and fetal or neonatal loss.
Laboratory Diagnosis of Thalassemia Syndromes
Laboratory Testing
Alpha-thalassemia usually is diagnosed from the family history and the absence of beta-thalassemia trait or iron deficiency anemia. The hemoglobin and hematocrit usually are within the normal range, but a marked microcytosis of less than 70 fL/cell is present. Patients who have alpha-thalassemia trait do not have increased levels of hemoglobin A 2 . There is no convenient laboratory test for diagnosing the alpha-thalassemia syndromes. Research techniques can detect the amount of alpha-and beta-globin chain production in a patient's reticulocytes. Such studies indicate that the beta/alpha production ratio is greater than 1 if alpha-chain synthesis is impaired, as in alpha-thalassemia trait (mean ratio, 1.3) or hemoglobin H disease (mean ratio, 2.6). Molecular techniques can detect the defective or absent alpha genes, and these will become more readily available for clinical diagnosis.
Treatment
No treatment is necessary for patients who have alphathalassemia trait. Patients who have hemoglobin H disease may require the administration of folic acid, transfusion therapy, and in rare instances of hypersplenism, splenectomy. Bart's hemoglobinopathy usually results in neonatal death. However, patients rarely have been salvaged with intrauterine transfusions and subsequent stem cell transplantation, which should be considered the treatment of choice if a donor is available.
Indication for Referral
The suspicion of alpha-thalassemia trait in patients of Asian descent warrants consultation with a pediatric hematologist to make a definitive diagnosis and to provide a risk assessment for the potential of having a child who has Bart's hemoglobinopathy. Appropriate screening of the parents of an affected Asian child to determine if both are carriers is indicated. Referral may be helpful in excluding other hypochromic and microcytic anemias in patients of African descent. 
Hereditary Spherocytosis History and Physical Examination
The severity of hereditary spherocytosis varies greatly, but it frequently causes hemolytic disease and severe hyperbilirubinemia in the newborn. Alternatively, some children remain asymptomatic and are detected because they have splenomegaly or because a mild anemia is found on a routine examination. The history also may reveal the presence of jaundice, anemia, or a familial history of splenectomy, gallbladder disease, or hereditary spherocytosis. Those who have severe disease develop pallor, fatigue, jaundice, and exercise intolerance during childhood. Because of the increased red cell turnover, affected children may develop cholelithiasis, and they are susceptible to aplastic crisis, primarily as a result of parvovirus infection. The marrow failure in an aplastic crisis may result in severe, life-threatening anemia.
Approximately 75% of patients have a positive family history. The remaining 25% may represent new mutations or occasionally recessive inheritance or nonpaternity. Physical examination may reveal pallor, jaundice, and splenomegaly.
Pathogenesis, Signs, and Symptoms
Hereditary spherocytosis results from abnormalities in red cell membrane proteins such as spectrin, ankyrin, or protein band 3. The molecular basis for many of these defects has been defined. Physiologically, membrane is lost, resulting in a decrease in membrane surface area in relation to red cell volume. As a consequence, there is a change toward a spherical shape, which permits the cell to be destroyed prematurely in the spleen.
The diagnosis of hereditary spherocytosis also is suggested by asymptomatic splenomegaly. It is worthwhile to examine the child's parents if they are available because splenomegaly in a parent makes the diagnosis of hereditary spherocytosis likely even before laboratory data are obtained. Anemia may be present, but increased red cell production is reflected in an elevated reticulocyte percentage. Parvovirus and other viruses can suppress the reticulocytosis and cause an aplastic crisis with an acute profound anemia. The chronic hemolysis may result in cholelithiasis and cholecystitis in the first decade of life.
Hereditary spherocytosis is the most common of the hereditary red cell membrane disorders and usually is inherited as an autosomal dominant trait. It should be considered early in the differential diagnosis of neonatal jaundice along with hemolytic disease of the newborn resulting from maternal antibodies to ABO antigens that also may cause spherocytosis. In older children, hereditary spherocytosis should be distinguished from immunohemolytic anemias; both disorders feature large numbers of spherocytic red cells on the blood film. The latter is confirmed by the presence of a positive antiglobulin (Coombs) test. Other causes of spherocytosis are listed in Table 7 .
Laboratory Testing
A complete blood count and reticulocyte percentage may reveal anemia with a reticulocytosis that reflects increased red cell production in the absence of bleeding. A family history, splenomegaly, reticulocytosis, spherocytes present on the blood film, and an increased mean corpuscular hemoglobin concentration strongly suggest the diagnosis of hereditary spherocytosis. The presence of similar findings in a parent confirms this diagnosis, and no further testing is necessary. An antiglobulin test is required to eliminate immunohemolytic anemia from the differential diagnosis. The osmotic fragility test (Fig. 2) can detect spherocytes if there is uncertainty about their presence on the blood film, but it is not specific for the diagnosis of hereditary spherocytosis. In this test, spherocytic red cells hemolyze more readily in hypotonic solutions, particularly if they are incubated in the absence of added glucose overnight. Specific protein abnormalities in spectrin, ankyrin, or band 3 can be defined in research laboratories, as can the various molecular abnormalities.
Treatment
The pediatrician needs to establish the baseline for the patient's hemoglobin, hematocrit, and reticulocyte percentage. These measurements must be repeated in the presence of any febrile illness to ensure that the reticulocyte percentage has not fallen as a result of parvovirus or other viruses that can precipitate an aplastic crisis and a life-threatening fall in hemoglobin and hematocrit concentrations. The management of an aplastic crisis requires consultation with a hematologist. The spherocytes in hereditary spherocytosis are destroyed almost exclusively in the spleen, and splenectomy eliminates most of the hemolysis in this disorder. Splenectomy is recommended (after age 5 y) if the patient cannot maintain a hemoglobin of 10 g/dL (100 g/L) or a reticulocyte percentage less than 10% or if he or she has had an aplastic crisis. Folic acid (0.5 mg for those younger than age 5 y and 1 mg/24 h for those older than age 5 y) should be administered to prevent secondary folic acid deficiency. Transfusion therapy may be used in children younger than 2 years of age who have severe disease. Splenectomy is delayed to beyond 5 to 6 years, if possible, to avoid the heightened risk of postsplenectomy sepsis, although it may be performed earlier (between 2 and 5 y) in severe disease. Immunization with Haemophilus influenzae, Streptococcus pneumoniae (multivalent (23PS)), and Neisseria meningitidis vaccines is required prior to splenectomy, and penicillin prophylaxis is required indefinitely thereafter.
Indication for Referral
It is useful to consult a pediatric hematologist at the earliest possible time when hereditary spherocytosis is the potential diagnosis, so that all of the alternative diagnoses (Table 7) can be considered; the genetics of the disease discussed with the parents; and the issues relating to aplastic crises, the risk of cholelithiasis, potential splenic injury, and the need and timing for splenectomy reviewed. Once a management plan is established (either after birth or later), an annual visit to a hematologist is recommended for regular assessment of the need for splenectomy. The pediatrician needs to monitor the child's reticulocyte percentage closely when there is a febrile illness. A reticulocyte percentage well below the baseline heralds a marked decrease in hemoglobin and hematocrit. The child who has this type of aplastic crisis should be referred to the hematologist. 
